TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)
Author
Naini, V.
Ozguroglu, M.
Yu, M.
Darif, M.
Merseburger, A. S.
Chi, K. N.
Chowdhury, S.
Radziszewski, P.
Lebret, T.
Sternberg, C.
Sims, R. B.
Metadata
Show full item recordCollections
- Bildiri [64839]